
Venkys (India) Ltd Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Poultry business is expected to grow around 20% annually, supported by stable feed prices and easing raw material costs.
- Animal Health Products (AHP) segment growth projected at around 34%, driven by the new AHP plant becoming operational by end FY2022 and ramping up in FY2023-24.
- AHP expansion is expected to add approximately 30% additional revenue in phase-1 after plant completion.
- Focus on specialized products within AHP like feed safety, nutritional supplements, and natural products will contribute to positive growth and better margins.
- Processed food division anticipates around 25% annual growth, largely fueled by QSR (Quick Service Restaurant) partnerships and new retail store openings.
- The overall company sales turnover witnessed 40% growth in FY2022; similar momentum is targeted through product diversification and market expansion.
- Stability in input prices and improved consumer acceptance of higher product prices expected to support volume growth.
See what Venkys (India) Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or future fundraising through debt or equity in the transcript.
- The discussion primarily focuses on operational performance, market share, feed costs, and expansion plans such as the new AHP plant.
- Capex plans mentioned include Rs.35 Crores initial investment and another Rs.12-15 Crores in phase 2 for the AHP unit, but no specific details on raising funds for these.
- The management did not indicate any intention or plan for equity or debt fundraising during the call.
See what Venkys (India) Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Venky’s India Limited is setting up a second unit under its Animal Health Products (AHP) segment.
- Initial capital investment for the new AHP plant (Phase-1) is Rs. 35 Crores.
- Phase-2 will involve an additional Rs. 12 to 15 Crores investment.
- The expansion project is expected to be completed by November-December 2022.
- The new AHP unit is anticipated to generate around 30% additional revenue in Phase-1.
- Revenues from the AHP expansion are expected to impact FY2023-24.
- The new plant targets specialized areas such as feed safety, nutritional supplements, and natural products to enhance bottom-line growth.
Track Venkys (India) Ltd — get its next earnings analysis in your feed
How does Venkys (India) Ltd rank vs peers in Food Products?
Pro featureHow does Venkys (India) Ltd rank in Food Products?
Compare Venkys (India) Ltd against every Food Products company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Venkys (India) Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q3 FY24 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q2 FY22 earnings call →
- Q4 FY21 earnings call →
- Q3 FY21 earnings call →
Others in Food Products this season
- Prataap Snacks Ltd (Q2 FY27)
Q2 FY27 income from operations was ₹540.95 crore, a 25.9% increase year-on-year (YoY). Key results statement takeaways from Prataap Snacks Ltd's Q2 FY27 results
- Madhusudan Masa (Q2 FY27)
4,158.28 lakh (Q2 2025), approximately +118% YoY. Key results statement takeaways from Madhusudan Masala Ltd's Q2 FY27 results statement — and how it ranks agai
- Vadilal Industries Ltd (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹462.56 crore (Consolidated, Page 11) . Key results statement takeaways from Vadilal Industrie
- Wardwizard Foods & Beverages Ltd (Q1 FY27)
Revenue for Q1 FY27 (June 2026 quarter) is ₹17.03 Cr, up from ₹13.20 Cr in Q1 FY26, reflecting a strong year-on-year growth. Key investor presentation takeaways